181 related articles for article (PubMed ID: 16953649)
1. Rivastigmine: in Parkinson's disease dementia.
Siddiqui MA; Wagstaff AJ
CNS Drugs; 2006; 20(9):739-47; discussion 748-50. PubMed ID: 16953649
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase inhibitors for Parkinson's disease dementia.
Maidment I; Fox C; Boustani M
Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine for dementia associated with Parkinson's disease.
Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
[TBL] [Abstract][Full Text] [Related]
4. Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
Wesnes K
Drugs Today (Barc); 2007 Jun; 43(6):349-59. PubMed ID: 17612707
[TBL] [Abstract][Full Text] [Related]
5. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
[TBL] [Abstract][Full Text] [Related]
6. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension.
Oertel W; Poewe W; Wolters E; De Deyn PP; Emre M; Kirsch C; Hsu C; Tekin S; Lane R
Drug Saf; 2008; 31(1):79-94. PubMed ID: 18095748
[TBL] [Abstract][Full Text] [Related]
7. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.
Devos D; Moreau C; Maltête D; Lefaucheur R; Kreisler A; Eusebio A; Defer G; Ouk T; Azulay JP; Krystkowiak P; Witjas T; Delliaux M; Destée A; Duhamel A; Bordet R; Defebvre L; Dujardin K
J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):668-74. PubMed ID: 24218528
[TBL] [Abstract][Full Text] [Related]
8. Rivastigmine and Parkinson dementia complex.
Moretti R; Torre P; Vilotti C; Antonello RM; Pizzolato G
Expert Opin Pharmacother; 2007 Apr; 8(6):817-29. PubMed ID: 17425477
[TBL] [Abstract][Full Text] [Related]
9. The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen.
Henderson EJ; Lord SR; Close JC; Lawrence AD; Whone A; Ben-Shlomo Y
BMC Neurol; 2013 Dec; 13():188. PubMed ID: 24299497
[TBL] [Abstract][Full Text] [Related]
10. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
Bullock R; Cameron A
Curr Med Res Opin; 2002; 18(5):258-64. PubMed ID: 12240787
[TBL] [Abstract][Full Text] [Related]
11. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
[TBL] [Abstract][Full Text] [Related]
12. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.
Dujardin K; Devos D; Duhem S; Destée A; Marié RM; Durif F; Lacomblez L; Touchon J; Pollak P; Péré JJ
J Neurol; 2006 Sep; 253(9):1154-9. PubMed ID: 16998649
[TBL] [Abstract][Full Text] [Related]
13. Rivastigmine for dementia associated with Parkinson's disease.
Harada CN; Shega JW; Sachs GA
N Engl J Med; 2005 Mar; 352(13):1387; author reply 1387. PubMed ID: 15800242
[No Abstract] [Full Text] [Related]
14. Rivastigmine: new indication. Dementia and Parkinson's disease: no thank you!
Prescrire Int; 2007 Apr; 16(88):66. PubMed ID: 17458048
[TBL] [Abstract][Full Text] [Related]
15. Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease.
Cummings JL
J Neurol Neurosurg Psychiatry; 2005 Jul; 76(7):903-4. PubMed ID: 15965192
[No Abstract] [Full Text] [Related]
16. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living.
Olin JT; Aarsland D; Meng X
Dement Geriatr Cogn Disord; 2010; 29(6):510-5. PubMed ID: 20523050
[TBL] [Abstract][Full Text] [Related]
17. Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.
Gurevich TY; Shabtai H; Korczyn AD; Simon ES; Giladi N
Mov Disord; 2006 Oct; 21(10):1663-6. PubMed ID: 16941467
[TBL] [Abstract][Full Text] [Related]
18. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.
Weintraub D; Somogyi M; Meng X
Am J Alzheimers Dis Other Demen; 2011 Sep; 26(6):443-9. PubMed ID: 22009228
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease.
Giladi N; Shabtai H; Gurevich T; Benbunan B; Anca M; Korczyn AD
Acta Neurol Scand; 2003 Nov; 108(5):368-73. PubMed ID: 14616309
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.
McKeith I; Del Ser T; Spano P; Emre M; Wesnes K; Anand R; Cicin-Sain A; Ferrara R; Spiegel R
Lancet; 2000 Dec; 356(9247):2031-6. PubMed ID: 11145488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
